Blog
RSS FeedPosted by Michael Wonder on 15 May 2022
Digital health devices must prove a benefit to get reimbursement
13 May 2022 - Digital health care companies should prove that their devices can improve the quality of patient care ...
Posted by Michael Wonder on 05 May 2022
Aadi Bioscience announces unique permanent J code issued for Fyarro from Centers for Medicare and Medicaid Services
4 May 2022 - Effective 1 July J code will enable a streamlined reimbursement process for Fyarro. ...
Posted by Michael Wonder on 04 May 2022
UnitedHealthcare restricts coverage of Aduhelm, following Medicare
2 May 2022 - UnitedHealthcare is restricting insurance coverage of Aduhelm across all of its health plans, saying the drug ...
Posted by Michael Wonder on 04 Apr 2022
Digital Medicine Society launches toolkit to support reimbursement for new drugs developed using digital outcomes
4 April 2022 - New essential resources ensure that patients will benefit without delay following regulatory acceptance of digital outcomes. ...
Posted by Michael Wonder on 04 Apr 2022
Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame
3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...
Posted by Michael Wonder on 22 Mar 2022
Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler
22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...
Posted by Michael Wonder on 14 Dec 2021
New hope offered to rare disease patients
14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...
Posted by Michael Wonder on 09 Dec 2021
InnoCare announces inclusion of orelabrutinib in China National Reimbursement Drug List
2 December 2021 - InnoCare Pharma announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement ...
Posted by Michael Wonder on 07 Dec 2021
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer
3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...
Posted by Michael Wonder on 07 Dec 2021
China clears insurance coverage for Kainos Medicine’s HIV drug
6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has ...
Posted by Michael Wonder on 07 Dec 2021
Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy
2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...
Posted by Michael Wonder on 07 Dec 2021
BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib
2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...
Posted by Michael Wonder on 07 Dec 2021
Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...
Posted by Michael Wonder on 04 Dec 2021
Drug makers cut prices by 62% on average to get China state insurance listing
4 December 2021 - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be ...
Posted by Michael Wonder on 13 Nov 2021
CMS repeals MCIT/R&N rule; will consider other coverage pathways to enhance access to innovative medical devices
12 November 2021 - Today, CMS is rescinding the Medicare Coverage of Innovative Technology and Definition of “Reasonable and Necessary” (MCIT/R&N) ...